The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study

PurposeLong-term survival benefit of anthracyclines for human epidermal growth factor receptor 2 (HER2)-positive breast cancer is clear. In the neoadjuvant treatment, compared with the monoclonal antibody such as trastuzumab and pertuzumab, the clinical benefit of pyrotinib, a new small-molecule tyr...

Full description

Bibliographic Details
Main Authors: Fu Li, Yimin Liang, Ming Luo, Jiayue Shen, Taosheng Zhou, Yajing Liang, Xiaoqi Tang, Huiming Yuan, Jian Zeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
human epidermal growth factor receptor 2 positive
breast cancer
neoadjuvant therapy
pyrotinib
real-world study
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1041111/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1041111/full

Similar Items